Search

VP025

VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation. … It is considered to be a systemic anti-inflammatory and neuroprotective agent.

Alanosine

An amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities.

Inbakicept

It is one of the active ingredients in Anktiva, a combination product also containing [nogapendekin alfa], where a single inbakicept is complexed with two nogapendekin alfa components. … [A263617, A263622] Inbakicept, in combination with nogapendekin alfa, mimics the actions of IL-15, stimulating the activation and proliferation of natural killer cells and CD8+ memory T cells, which also

Flupirtine

Flupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. … It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.

Clesrovimab

[A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … to provide passive immunization against RSV infection as an alternative means of protection.

Thiram

Thiram may be used in dermatology as a scabicide [T436]. … Thiram is mainly used as a fungicide for plants and treatment for seeds, however, this use is being investigated for safety in many markets including Canada [L5425].

BNC105

Isaralgagene civaparvovec

It is developed by Sangamo Therapeutics and investigated in Fabry Disease. … Isaralgagene civaparvovec, formerly known as ST-920, is liver-tropic rAAV 2/6 vector carrying the cDNA for human alpha-galactosidase A (α-Gal A) enzyme.

EGT-201

EGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the alpha-N-acetyglucosaminidase (NAGLU) transgene. … Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type B.[L45939]

Norclozapine

It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today. … ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia.